Q-omics provides the consensus-scored MOB2 profile across patient tissues and cancer cell-line models. MOB2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MOB2 is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, MOB2 protein abundance shows 22,177 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight UVM, BLCA, and LUAD as cancer lineages where MOB2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOB2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOB2 survival associations across molecular data types. MOB2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOB2 RNA expression–survival associations across cancer types. High MOB2 expression shows unfavorable associations in LIHC, ACC and COAD, but favorable associations in UVM, KIRC and SARC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify UVM as the clearest survival context for MOB2 RNA expression.
This table summarizes MOB2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in BLCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MOB2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOB2 shows lower tumor expression in BLCA, LUAD and UCEC and higher tumor expression in LIHC, KIRC and CHOL. The BLCA box plot shows higher MOB2 RNA expression in normal versus tumor tissue (log2 FC = −0.974, t-test p < 0.001).
This table shows molecular features associated with MOB2 in patient tissues and cancer cell lines. In patient samples, MOB2 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, MOB2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
